Nathaniel Barry , Eng-Siew Koh , Martin A. Ebert , Alisha Moore , Roslyn J. Francis , Pejman Rowshanfarzad , Ghulam Mubashar Hassan , Sweet P. Ng , Michael Back , Benjamin Chua , Mark B. Pinkham , Andrew Pullar , Claire Phillips , Joseph Sia , Peter Gorayski , Hien Le , Suki Gill , Jeremy Croker , Nicholas Bucknell , Catherine Bettington , Andrew M. Scott
{"title":"评估 FET PET 对放疗靶区划分的影响：前瞻性多中心试验评估胶质母细胞瘤FET PET（FIG）研究的放射肿瘤学认证计划结果 - TROG 18.06","authors":"Nathaniel Barry , Eng-Siew Koh , Martin A. Ebert , Alisha Moore , Roslyn J. Francis , Pejman Rowshanfarzad , Ghulam Mubashar Hassan , Sweet P. Ng , Michael Back , Benjamin Chua , Mark B. Pinkham , Andrew Pullar , Claire Phillips , Joseph Sia , Peter Gorayski , Hien Le , Suki Gill , Jeremy Croker , Nicholas Bucknell , Catherine Bettington , Andrew M. Scott","doi":"10.1016/j.phro.2024.100568","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and purpose</h3><p>The [18]F-fluoroethyl-<span>l</span>-tyrosine (FET) PET in Glioblastoma (FIG) study is an Australian prospective, multi-centre trial evaluating FET PET for newly diagnosed glioblastoma management. The Radiation Oncology credentialing program aimed to assess the feasibility in Radiation Oncologist (RO) derivation of standard-of-care target volumes (TV<sub>MR</sub>) and hybrid target volumes (TV<sub>MR+FET</sub>) incorporating pre-defined FET PET biological tumour volumes (BTVs).</p></div><div><h3>Materials and methods</h3><p>Central review and analysis of TV<sub>MR</sub> and TV<sub>MR+FET</sub> was undertaken across three benchmarking cases. BTVs were pre-defined by a sole nuclear medicine expert. Intraclass correlation coefficient (ICC) confidence intervals (CIs) evaluated volume agreement. RO contour spatial and boundary agreement were evaluated (Dice similarity coefficient [DSC], Jaccard index [JAC], overlap volume [OV], Hausdorff distance [HD] and mean absolute surface distance [MASD]). Dose plan generation (one case per site) was assessed.</p></div><div><h3>Results</h3><p>Data from 19 ROs across 10 trial sites (54 initial submissions, 8 resubmissions requested, 4 conditional passes) was assessed with an initial pass rate of 77.8 %; all resubmissions passed. TV<sub>MR+FET</sub> were significantly larger than TV<sub>MR</sub> (p < 0.001) for all cases. RO gross tumour volume (GTV) agreement was moderate-to-excellent for GTV<sub>MR</sub> (ICC = 0.910; 95 % CI, 0.708–0.997) and good-to-excellent for GTV<sub>MR+FET</sub> (ICC = 0.965; 95 % CI, 0.871–0.999). GTV<sub>MR+FET</sub> showed greater spatial overlap and boundary agreement compared to GTV<sub>MR</sub>. For the clinical target volume (CTV), CTV<sub>MR+FET</sub> showed lower average boundary agreement versus CTV<sub>MR</sub> (MASD: 1.73 mm vs. 1.61 mm, p = 0.042). All sites passed the planning exercise.</p></div><div><h3>Conclusions</h3><p>The credentialing program demonstrated feasibility in successful credentialing of 19 ROs across 10 sites, increasing national expertise in TV<sub>MR+FET</sub> delineation.</p></div>","PeriodicalId":36850,"journal":{"name":"Physics and Imaging in Radiation Oncology","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405631624000381/pdfft?md5=38b001d63ba09a46731b378b207e1349&pid=1-s2.0-S2405631624000381-main.pdf","citationCount":"0","resultStr":"{\"title\":\"[18]F-fluoroethyl-l-tyrosine positron emission tomography for radiotherapy target delineation: Results from a Radiation Oncology credentialing program\",\"authors\":\"Nathaniel Barry , Eng-Siew Koh , Martin A. Ebert , Alisha Moore , Roslyn J. Francis , Pejman Rowshanfarzad , Ghulam Mubashar Hassan , Sweet P. Ng , Michael Back , Benjamin Chua , Mark B. Pinkham , Andrew Pullar , Claire Phillips , Joseph Sia , Peter Gorayski , Hien Le , Suki Gill , Jeremy Croker , Nicholas Bucknell , Catherine Bettington , Andrew M. Scott\",\"doi\":\"10.1016/j.phro.2024.100568\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background and purpose</h3><p>The [18]F-fluoroethyl-<span>l</span>-tyrosine (FET) PET in Glioblastoma (FIG) study is an Australian prospective, multi-centre trial evaluating FET PET for newly diagnosed glioblastoma management. The Radiation Oncology credentialing program aimed to assess the feasibility in Radiation Oncologist (RO) derivation of standard-of-care target volumes (TV<sub>MR</sub>) and hybrid target volumes (TV<sub>MR+FET</sub>) incorporating pre-defined FET PET biological tumour volumes (BTVs).</p></div><div><h3>Materials and methods</h3><p>Central review and analysis of TV<sub>MR</sub> and TV<sub>MR+FET</sub> was undertaken across three benchmarking cases. BTVs were pre-defined by a sole nuclear medicine expert. Intraclass correlation coefficient (ICC) confidence intervals (CIs) evaluated volume agreement. RO contour spatial and boundary agreement were evaluated (Dice similarity coefficient [DSC], Jaccard index [JAC], overlap volume [OV], Hausdorff distance [HD] and mean absolute surface distance [MASD]). Dose plan generation (one case per site) was assessed.</p></div><div><h3>Results</h3><p>Data from 19 ROs across 10 trial sites (54 initial submissions, 8 resubmissions requested, 4 conditional passes) was assessed with an initial pass rate of 77.8 %; all resubmissions passed. TV<sub>MR+FET</sub> were significantly larger than TV<sub>MR</sub> (p < 0.001) for all cases. RO gross tumour volume (GTV) agreement was moderate-to-excellent for GTV<sub>MR</sub> (ICC = 0.910; 95 % CI, 0.708–0.997) and good-to-excellent for GTV<sub>MR+FET</sub> (ICC = 0.965; 95 % CI, 0.871–0.999). GTV<sub>MR+FET</sub> showed greater spatial overlap and boundary agreement compared to GTV<sub>MR</sub>. For the clinical target volume (CTV), CTV<sub>MR+FET</sub> showed lower average boundary agreement versus CTV<sub>MR</sub> (MASD: 1.73 mm vs. 1.61 mm, p = 0.042). All sites passed the planning exercise.</p></div><div><h3>Conclusions</h3><p>The credentialing program demonstrated feasibility in successful credentialing of 19 ROs across 10 sites, increasing national expertise in TV<sub>MR+FET</sub> delineation.</p></div>\",\"PeriodicalId\":36850,\"journal\":{\"name\":\"Physics and Imaging in Radiation Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2024-03-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2405631624000381/pdfft?md5=38b001d63ba09a46731b378b207e1349&pid=1-s2.0-S2405631624000381-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Physics and Imaging in Radiation Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2405631624000381\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Physics and Imaging in Radiation Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405631624000381","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
[18]F-fluoroethyl-l-tyrosine positron emission tomography for radiotherapy target delineation: Results from a Radiation Oncology credentialing program
Background and purpose
The [18]F-fluoroethyl-l-tyrosine (FET) PET in Glioblastoma (FIG) study is an Australian prospective, multi-centre trial evaluating FET PET for newly diagnosed glioblastoma management. The Radiation Oncology credentialing program aimed to assess the feasibility in Radiation Oncologist (RO) derivation of standard-of-care target volumes (TVMR) and hybrid target volumes (TVMR+FET) incorporating pre-defined FET PET biological tumour volumes (BTVs).
Materials and methods
Central review and analysis of TVMR and TVMR+FET was undertaken across three benchmarking cases. BTVs were pre-defined by a sole nuclear medicine expert. Intraclass correlation coefficient (ICC) confidence intervals (CIs) evaluated volume agreement. RO contour spatial and boundary agreement were evaluated (Dice similarity coefficient [DSC], Jaccard index [JAC], overlap volume [OV], Hausdorff distance [HD] and mean absolute surface distance [MASD]). Dose plan generation (one case per site) was assessed.
Results
Data from 19 ROs across 10 trial sites (54 initial submissions, 8 resubmissions requested, 4 conditional passes) was assessed with an initial pass rate of 77.8 %; all resubmissions passed. TVMR+FET were significantly larger than TVMR (p < 0.001) for all cases. RO gross tumour volume (GTV) agreement was moderate-to-excellent for GTVMR (ICC = 0.910; 95 % CI, 0.708–0.997) and good-to-excellent for GTVMR+FET (ICC = 0.965; 95 % CI, 0.871–0.999). GTVMR+FET showed greater spatial overlap and boundary agreement compared to GTVMR. For the clinical target volume (CTV), CTVMR+FET showed lower average boundary agreement versus CTVMR (MASD: 1.73 mm vs. 1.61 mm, p = 0.042). All sites passed the planning exercise.
Conclusions
The credentialing program demonstrated feasibility in successful credentialing of 19 ROs across 10 sites, increasing national expertise in TVMR+FET delineation.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
